15 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
9 Nov 23
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
8:16am
of the expected mOS in 50 patients (Arm A and B).
▪The observed increase in diversity of the T-cell receptor repertoire associated with improved survival
8-K
EX-99.1
CADL
Candel Therapeutics Inc
18 Oct 23
Regulation FD Disclosure
11:31am
the expansion of the T-cell repertoire diversity as well as HSV-1 immune status, correlate with survival suggesting that CAN-3110 can enhance anti-cancer immune … . Accordingly, we observed increased diversity of the T-cell receptor repertoire after a single injection of CAN-3110 in recurrent HGG patients. We have
8-K
EX-99.1
dhx 8yj31kj
19 May 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
ayma 72km34a0wuq
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
EX-99.1
6bejhk16kh
18 Nov 22
Other Events
8:30am
DEF 14A
vrdlihyig 8m
2 Sep 22
Definitive proxy
8:30am
424B4
xiwd5wgwienf rls
28 Jul 21
Prospectus supplement with pricing info
4:02pm
S-1/A
5bz4nwofefp1bo3i leo
16 Jul 21
IPO registration (amended)
6:07am
S-1
h4n74lnyu4u4hsv
25 Jun 21
IPO registration
5:28pm
DRS/A
ox8foh4sy4ag29n
31 Mar 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next